首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Investigation of the Mechanism of Traditional Chinese Medicines in Angiogenesis through Network Pharmacology and Data Mining
【24h】

Investigation of the Mechanism of Traditional Chinese Medicines in Angiogenesis through Network Pharmacology and Data Mining

机译:通过网络药理学和数据挖掘对血管生成中的中药机制的研究

获取原文
       

摘要

Although traditional Chinese medicine is effective and safe for the treatment of angiogenesis, the in vivo intervention mechanism is diverse, complex, and largely unknown. Therefore, we aimed to explore the active ingredients of traditional Chinese medicine and their mechanisms of action against angiogenesis. Data on angiogenesis-related targets were collected from GeneCards, Therapeutic Target Database, Online Mendelian Inheritance in Man, DrugBank, and DisGeNET. These were matched to related molecular compounds and ingredients in the traditional Chinese medicine system pharmacology platform. The data were integrated and based on the condition of degree 1, and relevant literature, target-compound, compound-medicine, and target-compound-medicine networks were constructed using Cytoscape. Molecular docking was used to predict the predominant binding combination of core targets and components. We obtained 79 targets for angiogenesis; 41 targets were matched to 3839 compounds, of which 110 compounds were selected owing to their high correlation with angiogenesis. Fifty-five combinations in the network were obtained by molecular docking, among which PTGS2-astragalin (?9.18?kcal/mol), KDR-astragalin (?7.94?kcal/mol), PTGS2-quercetin (?7.41?kcal/mol), and PTGS2-myricetin (?7.21?kcal/mol) were top. These results indicated that the selected potential core compounds have good binding activity with the core targets. Eighty new combinations were obtained from the network, and the top combinations based on affinity were KDR-beta-carotene (?10.13?kcal/mol), MMP9-beta-sitosterol (?8.04?kcal/mol), MMP9-astragalin (?7.82?kcal/mol), and MMP9-diosgenin (?7.51?kcal/mol). The core targets included PTGS2, KDR, VEGFA, and MMP9. The essential components identified were astragalin, kaempferol, myricetin, quercetin, and β -sitosterol. The crucial Chinese medicines identified included Polygoni Cuspidati Rhizoma et Radix, Morus alba Root Bark, and Forsythiae Fructus. By systematically analysing the ingredients of traditional Chinese medicine and their targets, it is possible to determine their potential mechanisms of action against pathological angiogenesis. Our study provides a basis for further research and the development of new therapeutics for angiogenesis.
机译:虽然中药对血管生成的治疗有效和安全,但体内干预机制是多样的,复杂,很大程度上未知。因此,我们旨在探索中药的活性成分及其对血管生成的作用机制。从Genecards,治疗目标数据库,在线孟德梅的继承中收集有关血管生成相关靶标的数据,在人,药物银行和撤购中。这些与中药系统药理学平台中的相关分子化合物和成分匹配。数据已集成并基于学位的条件& 1,以及使用Cytoscape构建相关文献,靶向化合物,复合药物和靶复合药物网络。分子对接用于预测核心靶和组分的主要结合组合。我们获得了79个血管生成的目标; 41靶与3839种化合物匹配,由于其与血管生成的高相关,选择了110种化合物。通过分子对接获得网络中的五十五种组合,其中PTGS2-黄芪(β7.18kcal / mol),Kdr-Astragalin(α.7.94?kcal / mol),Ptgs2-槲皮素(β7.41?kcal / mol) ,和ptgs2-myricetin(?7.21?kcal / mol)是顶部。这些结果表明,所选潜在的核心化合物具有良好的结合活性,具有核心靶标。从网络中获得八十个新组合,基于亲和力的顶部组合是KDR-β-胡萝卜素(α10.13?kcal / mol),MMP9-β-苯甲酸溶胶(β-kcal / mol),mmp9-黄芪(? 7.82?kcal / mol),和mmp9-二氧胞苷(α.7.51?kcal / mol)。核心目标包括PTGS2,KDR,VEGFA和MMP9。鉴定的基本组分是黄芪,Kaempferol,Myricetin,槲皮素和β-辛甾醇。鉴定的至关重要的中药包括Polygoni Cuspidati Rhizoma等radix,Morus alba根吠叫和连翘果酱。通过系统地分析中药的成分及其目标,可以确定它们对病理血管生成的潜在作用机制。我们的研究为进一步研究和开发血管生成的新治疗方法提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号